Erratum
After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as “Plasma Adiponectin, ng/ml” instead of “PEPCK, % of Vehicle”. (Please see a corrected version of Fig. 7 below).
Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel
Reference
Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/1758-5996-6-104.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Ezrokhi, M., Luo, S., Trubitsyna, Y. et al. Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr 7, 61 (2015). https://doi.org/10.1186/s13098-015-0056-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13098-015-0056-x